摘要
目的:评价艾司西酞普兰与西酞普兰治疗抑郁症的临床疗效和安全性。方法:随机选择门诊、住院抑郁症患者86例,分为艾司西酞普兰与西酞普兰组各43例,分别口服艾司西酞普兰10～20mg/d及西酞普兰20～40mg/d,疗程为6Wk。于基线及服药Wk1、2、4、6末,采用汉密尔顿抑郁量表(HAMD-17)和临床总体印象量表-病情严重程度(CGI-SI)评定疗效,副反应量表(TESS)评定不良反应。结果:治疗Wk6末,艾司西酞普兰组与西酞普兰组HAMD-17总减分率分别为(68.35±11.24)%和(67.23±12.37)%,艾司西酞普兰组显效率为72%,有效率为84%,西酞普兰组组显效率为67%,有效率为81%,两组间疗效差异无显著意义(p>0.05),在Wk1末时,试验第一作者王来海组比对照组的HAMD-17的减分及减分率明显增加(p<0.05)。试验组和对照组不良反应发生率分别为20%和25%,两组的不良反应轻微,安全性好,常见的不良反应有恶心、头痛等。结论:艾司西酞普兰的抗抑郁作用疗效肯定,使用安全,与西酞普兰疗效相当。
Objective ： To evaluate the efficacy and safety of escitalopram and citalopram in the treatment of depression. Methods ： In this 6-wk randomized study, 86 patients diagnosed with depression were divided randomizely into escitalopram （10-20 mg/d） group and citalopram （20-40 mg/d） group with 43 in each group. The efficacy and safety were assessed with Hamilton Depression Scale （HAMD）, Clinical Global Impression- Severity of Illness （CGI-SI） and Treatment Emergent Symptom Score （TESS） from baseline and at Wkl, 2,4,6 of treatment, respectively. Results ： The decreasing rates on HAMD-17 in the escitalopram group was （68.35±11.24） % and that of the citalopram group （67.23±12.37） %, and obvious effective rates and effective rates of tested and controlled group were 72% and 84%, 67% and 81% respectively, the clinical efficacy of the two groups showed no significant difference （P 〉0.05）, at the end of first week, decreasing score and decreasing rates on HAMD-17 in the escitalopram group were higher than those of the control group （P 〈0.05） . No severe side-effects were found. The adverse reaction rates in the tested and controlled group were 20% and 25% respectively. The common adverse reactions were nausea and headache. Conclusions ： escitalopram is as effective and safe as citalopram in treatment of depression.
出处
《中国药物评价》
2012年第1期48-50,共3页
Chinese Journal of Drug Evaluation
基金
河南省卫生科技创新型人才工程专项(2011-2015)
